
    
      This is a randomized, open-label, single-dose, two-way crossover study evaluating the PK and
      PD equivalence following SC administration of test and reference product in healthy
      volunteers. The study will be conducted at a single Phase 1 unit.

      After meeting the selection criteria, subjects will be randomly assigned to 1 of the 2
      treatment sequences:

        -  Filgrastim Hospira (US) followed by US-approved Neupogen®

        -  US-approved Neupogen® followed by Filgrastim Hospira (US)

      Subjects will receive one of the drugs in the first Period and the other drug in the other
      Period.
    
  